Valsts: Īrija
Valoda: angļu
Klimata pārmaiņas: HPRA (Health Products Regulatory Authority)
Live canine parvovirus strain NL-35-D
Zoetis Belgium S.A.
QI07AD01
Live canine parvovirus strain NL-35-D
.
Solution for injection
POM: Prescription Only Medicine as defined in relevant national legislation
Dogs
canine parvovirus
Immunological - Live Vaccine
Authorised
2014-09-12
Health Products Regulatory Authority 06 October 2017 CRN000WDG Page 1 of 5 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Vanguard CPV 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Quantity per 1 ml dose ACTIVE SUBSTANCE(S): Live attenuated canine Parvovirus, strain NL-35-D, low passage, minimum : 10 7.0 CCID 50 * *Cell culture infectious dose-50 For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. The liquid is slightly turbid, reddish in colour. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs from 5 weeks of age. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Active immunisation of dogs to prevent mortality and clinical signs including leucopenia and reduce viral shedding caused by canine parvovirus (types 2a, 2b and 2c). Onset of immunity occurs by approximately two weeks after the last dose of the basic vaccination scheme. Onset of immunity for the canine parvovirus component (type 2b) occurs 7 days after a single dose when animals are vaccinated from 9 weeks of age. The duration of immunity is 12 months, after the last dose of the basic vaccination scheme based on serology/challenge data. 4.3 CONTRAINDICATIONS Do not use in unhealthy animals. Health Products Regulatory Authority 06 October 2017 CRN000WDG Page 2 of 5 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS The canine parvovirus vaccinal strain may be shed from vaccinated animals for a number of days following vaccination. However, due to the low pathogenicity of this strain, it is not necessary to keep vaccinated animals seperated from non-vaccinated animals. Due to the presence of maternally derived antibodies, a small percentage of pups may fail to mount an adequate immune response to vaccination and may be at risk from disease when the local disease challenge is sufficiently high. The percentage of puppies that fail to mount an adequate immune response to vaccination is greater when the final vaccination is given at 10 weeks of age than Izlasiet visu dokumentu